Hyperlioproteinämie und LDL-AphereseKlinische Erfahrungen mit dem H.E.L.P.-System

No question, one of the leading causal factors for early atherosclerosis and coronary heart disease (CHD) is the abundance of LDL-cholesterol in the blood, exceeding limits of 100 mg/dl. Thus, recommendations for therapy focus on LDL-levels less than 100 mg/dl. With the introduction of the statins--a very potent family of lipid lowering agents--such target levels can be achieved in most of the patients, resulting in a drastic decrease of LDL, CHD incidences, as well as in a reduction of cardiac and total mortality. There is, however, a remaining small group of patients, who is more or less resistant to an adequate combination of dietary and drug therapy. For these patients, various techniques of apheresis are available for over 15 years. Some of them have been approved by the FDA in the US and comparable regulatory offices in Europe. The most extensive experimental and clinical experience was gathered with the H.E.L.P.-system of B. Braun Melsungen, which differs from other apheresis techniques by its efficiency to eliminate LDL, Lp(a), Fibrinogen and CRP simultaneously. The clinical results obtained up to day with the apheresis clearly demonstrate a significant reduction of risk factors and clinical events, as well as an excellent long-term tolerance.     

PneuX?P.Y.TM-System

Background

Ventilator-associated pneumonia (VAP) is the most common nosocomial infection and causes substantial morbidity and mortality in intensive care units (ICU). Strategies are needed to reduce the risk of VAP. One opportunity to prevent VAP seems to be the PneuX P.Y. system available in Germany since?2009. The features of the system are a specially designed tube and a tracheal seal monitor.

Method

We examine the PneuX in long-term ventilated critically ill patients (duration of ventilation >7?days). All parameters needed to calculate the CPIS were taken and interpreted regarding pulmonary infections and compared between the PneuX and standard tube systems. To compare the results the t test and the ??² test were applied.

Results

A total of 30?consecutive surgical patients (16?women/14?men) with an average age of 65.8?years (SD?21?years) were treated with the PneuX system. The average duration of ventilation with the system was 12?days (SD?5.5?days). The mean CPIS for all patients with the PneuX was 3.1 (SD?1.26) and during standard tube application 4.38 (SD?1.8). This difference was significant (p<0.05).

Conclusion

The PneuX system has been designed to facilitate the provision of a number of evidence-based interventions that have been shown to reduce VAP and is easy to apply.     

P.T.C联合G.I诊断梗阻性肝胆疾病

目的通过P．T．C联合G．I观察和明确肝胆梗阻病变之所在和X线影像表现，指导临床治疗．方法用细肝穿针在X线透视下穿刺入肝内，并注入胆影葡胺，摄取肝内外之肝管和胆管的影像，和口服硫酸钡液涂布胃、十二指肠，观察胃、十二指肠的改变．联合了解肝、胆管与胃、十二指肠的直接和间接征象．结果P．T．C片清楚显示肝内之肝管呈树枝状影，本例右肝内肝管明显扩张，左肝内及肛门之左右肝管和胆总管均不显影，于肝门处呈各形态之残端改变；G．I则见胃小弯及十二指肠球部明显受压移位，球部粘膜及上缘不清两法联合所见示肝门处有占位病变存在，伴十二指肠球都受累．经手术、病理证实．结论P．T．C联合G．I检查，简便易行，较为安全，成功率高，对诊断肝胆梗阻性疾病具有很重要价值．     

Kongressprogramm. 36. Deutsche Koloproktologen-Kongress vom 11. bis 13. März 2010 in München

Kongressprogramm

Kongressprogramm. 36. Deutsche Koloproktologen-Kongress vom 11. bis 13. M?rz 2010 in München     

PSYCHIATRIC DISORDER.

21.1 SChizophre.ia2000214 Com即riSOn Ot nemonaPrlde(em应口a倪)七0 halo伴r盆dol通n the treatment of schlzophrenia.HUANGShuzhen(黄淑贞),et al.Beiiing Anding Hosp,Beijing,100088.Chin J Psyehiat1999书32(4):226一229. ob加ctlve:To investigate the effieaey and safety of nemon-apride in the rreatment of schi功phrenia.Met加ods:A total of 130inpatients who rnet CCMD一2一R eriteria for schizophrenia wererandomly assigned to treatment with nemonapride(n=67)orha1Operidol(n=63)for 8 weeks.The effi…